RUNX1T1 and leukemia: Thus, nanoparticle‐based drug delivery should be used to maintain release, decrease the dose of MLT, and enhance treatment efficiency.49 In addition, although MLT presents anti‐LSC activity in leukaemia cells carrying AML1‐ETO, whether MLT inhibits self‐renewal of LSC in leukaemia without AML1‐ETO is still unknown.